Kinetics of Glycoprotein-Specific Antibody Response in Patients with Severe Fever with Thrombocytopenia Syndrome

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne disease in East Asia that is causing high mortality. The Gn glycoprotein of the SFTS virus (SFTSV) has been considered to be an essential target for virus neutralization. However, data on anti-Gn glycoprotein antibody kinetics are limited. Therefore, we investigated the kinetics of Gn-specific antibodies compared to those of nucleocapsid protein (NP)-specific antibodies. A multicenter prospective study was performed in South Korea from January 2018 to September 2021. Adult patients with SFTS were enrolled. Anti-Gn-specific IgM and IgG were measured using an enzyme-linked immunosorbent assay. A total of 111 samples from 34 patients with confirmed SFTS were analyzed. Anti-Gn-specific IgM was detected at days 5–9 and peaked at day 15–19 from symptom onset, whereas the anti-NP-specific IgM titers peaked at days 5–9. Median seroconversion times of both anti-Gn- and NP-specific IgG were 7.0 days. High anti-Gn-specific IgG titers were maintained until 35–39 months after symptom onset. Only one patient lost their anti-Gn-specific antibodies at 41 days after symptom onset. Our data suggested that the anti-Gn-specific IgM titer peaked later than anti-NP-specific IgM, and that anti-Gn-specific IgG remain for at least 3 years from symptom onset.

[1]  Y. Ye,et al.  Time Course of Severe Fever With Thrombocytopenia Syndrome Virus and Antibodies in Patients by Long-Term Follow-Up Study, China , 2021, Frontiers in Microbiology.

[2]  T. Yoshikawa.  Vaccine Development for Severe Fever with Thrombocytopenia Syndrome , 2021, Viruses.

[3]  Ji Yeun Kim,et al.  Molecular Signatures of Inflammatory Profile and B-Cell Function in Patients with Severe Fever with Thrombocytopenia Syndrome , 2021, mBio.

[4]  S. Choi,et al.  Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome , 2020, Viruses.

[5]  Misun Kim,et al.  Prognostic Factors of Severe Fever with Thrombocytopenia Syndrome in South Korea , 2020, Viruses.

[6]  Steven B. Bradfute,et al.  2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. , 2020, Archives of virology.

[7]  Bian-Li Xu,et al.  Severe fever with thrombocytopenia syndrome: a systematic review and meta-analysis of epidemiology, clinical signs, routine laboratory diagnosis, risk factors, and outcomes , 2020, BMC Infectious Diseases.

[8]  Xiaomin Yan,et al.  Nucleocapsid protein-specific IgM antibody responses in the disease progression of severe fever with thrombocytopenia syndrome. , 2019, Ticks and tick-borne diseases.

[9]  Jinhe Kim,et al.  An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus , 2018, bioRxiv.

[10]  Yong Liu,et al.  Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection , 2018, Nature Communications.

[11]  Ji Yeun Kim,et al.  Rapid Diagnosis of Tick-Borne Illnesses by Use of One-Step Isothermal Nucleic Acid Amplification and Bio-Optical Sensor Detection. , 2018, Clinical chemistry.

[12]  Ji Yeun Kim,et al.  Kinetics of viral load and cytokines in severe fever with thrombocytopenia syndrome , 2018, Journal of Clinical Virology.

[13]  Yong Liu,et al.  Downregulation of Interferon-β and Inhibition of TLR3 Expression are associated with Fatal Outcome of Severe Fever with Thrombocytopenia Syndrome , 2017, Scientific Reports.

[14]  Hao Yu,et al.  Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome , 2017, Virology Journal.

[15]  Young Keun Kim,et al.  Severe Fever with Thrombocytopenia Syndrome in South Korea, 2013-2015 , 2016, PLoS neglected tropical diseases.

[16]  Yi Yang,et al.  Neutralizing Antibodies to Severe Fever with Thrombocytopenia Syndrome Virus 4 Years after Hospitalization, China , 2016, Emerging infectious diseases.

[17]  W. Liu,et al.  Characterization of immunological responses in patients with severe fever with thrombocytopenia syndrome: a cohort study in China. , 2015, Vaccine.

[18]  Shixia Wang,et al.  Concurrent Measurement of Dynamic Changes in Viral Load, Serum Enzymes, T Cell Subsets, and Cytokines in Patients with Severe Fever with Thrombocytopenia Syndrome , 2014, PloS one.

[19]  Wenhui Li,et al.  Nonmuscle Myosin Heavy Chain IIA Is a Critical Factor Contributing to the Efficiency of Early Infection of Severe Fever with Thrombocytopenia Syndrome Virus , 2013, Journal of Virology.

[20]  Mingming Huang,et al.  Human Antibody Neutralizes Severe Fever with Thrombocytopenia Syndrome Virus, an Emerging Hemorrhagic Fever Virus , 2013, Clinical and Vaccine Immunology.

[21]  F. Weber,et al.  Severe Fever with Thrombocytopenia Virus Glycoproteins Are Targeted by Neutralizing Antibodies and Can Use DC-SIGN as a Receptor for pH-Dependent Entry into Human and Animal Cell Lines , 2013, Journal of Virology.

[22]  Chuan Li,et al.  Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. , 2012, The Journal of infectious diseases.

[23]  Weizhong Yang,et al.  Fever with thrombocytopenia associated with a novel bunyavirus in China. , 2011, The New England journal of medicine.